Latest United States Startup Funding Rounds

Startup funding in United States: recent rounds, the companies behind them and their participating investors.

This page showsCountry: United States
Rounds
2,130
Jan 1 – Oct 9, 2026
Disclosed funding
$200B
1764 disclosed amounts
Median round
$24M
Of disclosed amounts
2,130 rounds
Funding rounds
CompanyAmountRoundSectorCountryInvestorsAnnounced
HarmoniIndustrial tech · United StatesCompany profile

A factory-orchestration platform connects workers, machines and business systems to coordinate production in real time.

A factory-orchestration platform connects workers, machines and business systems to coordinate production in real time.

$10MSeries AIndustrial techUnited StatesInvestors
BleeEnterprise software · United StatesCompany profile

Blee gives legal, compliance and marketing teams an AI-assisted system to review promotional content against their rules before publication and monitor websites, social media and partner channels afterward.

Blee gives legal, compliance and marketing teams an AI-assisted system to review promotional content against their rules before publication and monitor websites, social media and partner channels afterward.

$20MSeries AEnterprise softwareUnited StatesInvestors
Bluecore EnergyClimate tech · United StatesCompany profile

Building small nuclear reactors on floating barges for clean power to ports and nearby infrastructure

Building small nuclear reactors on floating barges for clean power to ports and nearby infrastructure

$40MSeed — additional capital within USD50m financingSeedClimate techUnited StatesInvestors
Moonwalk BiosciencesBiotech · United StatesCompany profile

Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027.

Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027.

$70MSeries BBiotechUnited StatesInvestors
Fab2Hardware · United StatesCompany profile

Fab2 develops chipmaking equipment and design software to shorten the path from chip design to fabrication.

Fab2 develops chipmaking equipment and design software to shorten the path from chip design to fabrication.

$500MSeries AHardwareUnited StatesInvestors
BrainChild BioBiotech · United StatesCompany profile

BrainChild Bio develops CAR T-cell therapies for tumors in the central nervous system, including pediatric brain cancers and glioblastoma.

BrainChild Bio develops CAR T-cell therapies for tumors in the central nervous system, including pediatric brain cancers and glioblastoma.

$116MSeries ABiotechUnited StatesInvestors
Undisclosed
Tokoshie, Inc.AI · United StatesCompany profile

The developer of Ignite0, a conversational CAD tool that turns text and images into editable three-dimensional models.

The developer of Ignite0, a conversational CAD tool that turns text and images into editable three-dimensional models.

UndisclosedFundingUndisclosedAIUnited StatesInvestors
ParlayXFintech · United StatesCompany profile

ParlayX provides institutional trading desks with a shared control and execution layer for prediction markets, including segregated capital, trader and bot permissions, non-custodial key management and order routing across venues.

ParlayX provides institutional trading desks with a shared control and execution layer for prediction markets, including segregated capital, trader and bot permissions, non-custodial key management and order routing across venues.

$1.3MPre-SeedPre-seedFintechUnited StatesInvestors
Gimlet LabsAI · United StatesCompany profile

Provides a cloud inference platform and compiler that distribute AI workloads across different processor types.

Provides a cloud inference platform and compiler that distribute AI workloads across different processor types.

$300MSeries BAIUnited StatesInvestors
Cloverleaf BioBiotech · United StatesCompany profile

Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical.

Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical.

$33MSeedBiotechUnited StatesInvestors

Active investors in this selection

All investors →

Ranked by rounds participated in · From Jan 1, 2026

  1. 1
    Y Combinator (YC)

    Nous Research, Santé, Vitalize

    125rounds
    3led
  2. 2
    Andreessen Horowitz (a16z)

    TypeSafe AI, Arena, Vesta

    94rounds
    18led
  3. 3
    General Catalyst

    Minerva Humanoids, Melius

    65rounds
    6led
  4. 4
    Alumni Ventures

    Savvy Wealth, Mona, American Supercritical

    55rounds
    0led
  5. 5
    Khosla Ventures

    Arena, Vinci, Conway Research

    54rounds
    5led

Latest digests

Archive →

Explore published rounds while the next edition is being prepared.

Browse rounds by topic